title: Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature.
abstract: Denosumab is a human monoclonal antibody representing a novel therapy of osteoporosis. Contrary to always other antiosteoporotic drugs, it is not contraindicated in advanced chronic kidney disease, as its pharmacokinetic does not differ from patients with normal kidney function. However, published case reports in chronic kidney disease (CKD) patients stopped the therapy after single dose because of hypocalcemia. We present a case of successful treatment of osteoporosis in a young hemodialysis patient with repeated denosumab doses.
authors.affiliation: Hemodialysis Centre, University Hospital Hradec Kralové, Czech Republic; Department of Internal Medicine II, Charles University, Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Dusilova Sulkova
authors.affiliation: Department of Internal Medicine IV, Charles University, Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic.
authors.forename: Jiri
authors.initials: J
authors.lastname: Horacek
authors.affiliation: Hemodialysis Centre, University Hospital Hradec Kralové, Czech Republic; Department of Internal Medicine III, Charles University, Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic.
authors.forename: Roman
authors.initials: R
authors.lastname: Safranek
authors.affiliation: Hemodialysis centre BBraun Avitum, Ustí nad Orlicí, Czech Republic.
authors.forename: Petr
authors.initials: P
authors.lastname: Gorun
authors.affiliation: Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
authors.forename: Ondrej
authors.initials: O
authors.lastname: Viklicky
authors.affiliation: Department of Clinical Biochemistry, Charles University, Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic.
authors.forename: Vladimir
authors.initials: V
authors.lastname: Palicka
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000069448:Denosumab; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D006435:Renal Dialysis
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D000069448:Denosumab
keywords: Bone density; Denosumab; Hemodialysis; Hypocalcemia; Parathormone